Could the DIO2 rs225014 (Thr92Ala) variant cause persistent hypothyroid symptoms despite normal TSH on levothyroxine?

The DIO2 rs225014 (Thr92Ala) genetic variant is a scientifically supported factor that explains why a subset of patients treated for hypothyroidism continues to experience symptoms despite achieving biochemical euthyroidism (normal TSH levels) on levothyroxine (L-T4) monotherapy.

Mechanistic evidence

The type 2 deiodinase (DIO2) enzyme is the primary catalyst for converting the pro-hormone T4 into the active hormone T3 within tissues, including the brain and muscle. The Thr92Ala polymorphism significantly impairs this process:

• Enzymatic dysfunction: The Ala92 variant results in approximately a 40% reduction in deiodinase activity compared to the wild-type Thr92 enzyme.
• Cellular stress and degradation: This reduction is driven by impaired protein stability and trafficking. The Ala92-DIO2 protein is ectopically localized to the Golgi apparatus rather than its intended cellular locations, triggering endoplasmic reticulum (ER) stress and the unfolded protein response (UPR).
• Reduced intracellular T3: This stress leads to increased ubiquitination and proteasomal degradation of the enzyme, lowering steady-state levels and resulting in localized T3 deficiency. This deficit is particularly impactful in the brain, where DIO2 is the main source of intracellular T3.

Clinical evidence and symptom persistence

Standard levothyroxine therapy relies on the body's ability to convert T4 to T3. However, the DIO2 polymorphism creates a conversion bottleneck that standard monitoring often misses.

• TSH limitations: TSH is primarily a marker of the pituitary gland's response to circulating T4. In carriers of the Ala92 variant, TSH may normalize even while other tissues remain in a state of "local hypothyroidism" due to poor intracellular conversion.
• Patient outcomes: Approximately 15% of the population are homozygous for this variant. Clinical studies have shown that these individuals frequently report persistent fatigue, cognitive impairment ("brain fog"), and decreased psychological well-being.
• Therapeutic response: Research indicates that patients with the Thr92Ala polymorphism are more likely to report symptomatic improvement and show a strong preference for combination T4 and T3 therapy (liothyronine), which bypasses the enzymatic conversion defect.

Bottom line

The DIO2 rs225014 polymorphism is a validated genetic cause for the persistence of hypothyroid symptoms in patients with normal TSH. It impairs the local conversion of T4 to active T3 through cellular stress and enzyme degradation, suggesting that standard T4 monotherapy may be insufficient for these individuals.